In an oral presentation at the ongoing American Society of Hematology (ASH) meeting, Johnson & Johnson’s (NYSE: JNJ) pharmaceutical arm Janssen has put forward a new analysis of data from Phase II and III studies of Imbruvica (ibrutinib).
The data show patients with relapsed/refractory mantle cell lymphoma (MCL) that were treated with Imbruvica earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability.
Imbruvica is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, jointly developed and commercialized by Janssen and Pharmacyclics, an AbbVie (NYSE: ABBV) subsidiary.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze